Premium
Evaluation of lipoprotein‐associated phospholipase A2 as a marker for renal microvasculopathy in adolescents with Type 1 diabetes
Author(s) -
Seyfarth J.,
Herebian D.,
Reinauer C.,
Baechle C.,
Roden M.,
Holl R. W.,
Reinehr T.,
Mayatepek E.,
Meissner T.,
Rosenbauer J.
Publication year - 2020
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.14086
Subject(s) - albuminuria , medicine , lipoprotein associated phospholipase a2 , endocrinology , lipoprotein(a) , diabetes mellitus , renal function , lipoprotein , surrogate endpoint , type 2 diabetes , lysophosphatidylcholine , cholesterol , phospholipid , biology , biochemistry , membrane , phosphatidylcholine
Aim To assess the relevance of lipoprotein‐associated phospholipase A2 activity as a diagnostic and prognostic marker for renal microvascular diseases. Methods We analysed lipoprotein‐associated phospholipase A2 activity and lysophosphatidylcholine levels (as a surrogate marker of oxidative stress) in 165 adolescents (aged 17.0 ± 2.3 years) with a history of Type 1 diabetes greater than 10 years. Clinical data were obtained from the German/Austrian nationwide Diabetes‐Patients Follow‐up (DPV) registry at blood collection and on average 2.4 ± 1.3 years later at follow‐up. Relationships between lipoprotein‐associated phospholipase A2 activity and clinical, demographic and laboratory variables, lysophosphatidylcholine levels and presence of albuminuria were evaluated by multivariable linear and logistic regression. Results Lipoprotein‐associated phospholipase A2 activity was higher in male than female adolescents ( P = 0.002). Albuminuria was present in 14% (22/158) of participants at baseline, and 5% (4/86) of participants without albuminuria at baseline developed albuminuria until follow‐up. Lipoprotein‐associated phospholipase A2 activity was associated neither with present nor with incident albuminuria. Lysophosphatidylcholine did not correlate with lipoprotein‐associated phospholipase A2 activity. Cross‐sectional bivariate correlation as well as multivariable linear regression analysis revealed a negative correlation of lipoprotein‐associated phospholipase A2 activity with HbA 1c and HDL ‐cholesterol. Conclusions Lipoprotein‐associated phospholipase activity was not associated with surrogate markers for oxidative stress and early diabetic nephropathy. The association of decreased lipoprotein‐associated phospholipase A2 activity with poor glucose control might limit its function as a predictor of micro‐ and macrovascular diseases in Type 1 diabetes.